ROS THERAPEUTICS
OPTIMIZING THE TREATMENT EXPERIENCE FOR CHILDREN WITH JIA AND OTHER AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS
About us
ROS Therapeutics is a development stage pharmaceutical company committed to optimize the treatment experience and address unmet needs of children with Juvenile Idiopathic Arthritis (JIA) and other autoimmune and chronic inflammatory conditions through an innovative proprietary best-in-class orally delivered methotrexate therapy; Trexior™.
Methotrexate (MTX) is a cornerstone treatment for JIA, one of the most common childhood diseases as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults.
Since the early 90’ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.
Several of the shortcomings of existing
methotrexate therapies, whether oral or injections, are sought overcome with Trexior.
News
March 01, 2021
October 5, 2020
July 01, 2021
June 01, 2022
September 20, 2022
Leadership
Hanne Damgaard Jensen
Chief Executive Officer,
Board Member
Christian Gunni Pedersen
Chief Financial Officer
Jens Kjeldsen-Kragh
Medical Director
Board Of Directors
Ulrik Spork
Co-founder, Chairman
Ricki Boye
Board Member
Morten Sandlykke
Board Member
Henrik Fenger
Board Member
Medical Advisors
Troels Herlin
Kristian Stengaard-Pedersen
CONTACT US
ROS Therapeutics ApS, Ole Maaløes vej 3, 2200 Copenhagen N, Denmark